drugset / Trial / NCT01888978
Molecularly Tailored Therapy for Pancreas Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Patient therapy is tailored according to the molecular profile of the patient's tumor.
Timeline
- Start
- 2012-12
- Primary completion
- 2016-06
- Completion
- 2018-01-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 35 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 65 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 50 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 180 mg/m2 | — |
| Subject | Leucovorin | Small molecule | 400 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | — |
| Subject | fluorouracil | Small molecule | 400 mg/m2 | — |
| Subject | fluorouracil | Small molecule | 2000 unknown | — |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | — |